Janssen

Article

Johnson & Johnson Receives Two Cancer Drug Approvals
11.08.2023 • News

Johnson & Johnson Receives Two Cancer Drug Approvals

The US FDA approved Akeega and Talvey late last week. Phase 3 trials validated Akeega's use in the treatment of patients with BRCA-positive prostate cancer. Talvey is authorized for patients with heavily pretreated multiple myeloma.